EMA Authorised: Clopidogrel ratiopharm (clopidogrel (as hydrogen sulfate)) — Teva B.V.

View source ↗

Summary

European Medicines Agency authorises Clopidogrel ratiopharm (clopidogrel hydrogen sulfate) for multiple cardiovascular indications including myocardial infarcti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Peripheral Vascular Disease
• Stroke

Drugs mentioned

• Clopidogrel ratiopharm (clopidogrel hydrogen sulfate)

Snippet

Status: Authorised. Therapeutic area: Myocardial Infarction;Acute Coronary Syndrome;Peripheral Vascular Diseases;Stroke. MAH: Teva B.V.. Decision date: 21/03/2024